BioCentury | Jan 11, 2016
Finance

Sowing season

...S.A. (Euronext:COX) Cetirizine Ocular itching associated with allergic conjunctivitis Submit NDA 1H16 Nicox S.A. (Euronext:COX) AzaSite...
BioCentury | Apr 13, 2015
Company News

Merck & Co. Inc, Akorn deal

...from 8% in the royalty rate paid to InSite from Akorn on net sales of AzaSite...
...million. Other royalty terms remain the same. Akorn has exclusive, North American rights to market AzaSite...
...Inc. , which licensed the rights from InSite in 2007. Merck acquired Inspire in 2011. AzaSite...
BioCentury | Feb 9, 2015
Company News

InSite, Nicox deal

...launch launch one of them in late 2017. AzaSite is a 1% formulation of azithromycin, AzaSite...
...a low-dose formulation of NSAID bromfenac. The products use InSite’s DuraSite ophthalmic drug delivery system. AzaSite...
BioCentury | Sep 8, 2014
Company News

InSite, Inspire deal

...AzaSite azithromycin in North America. Last year, Akorn acquired exclusive, North American rights to market AzaSite...
...9% if Akorn enters into settlements with third parties seeking to launch generic versions of AzaSite...
...drug delivery system, and AzaSite Xtra is a Durasite formulation of 2% azithromycin. Akorn markets AzaSite...
BioCentury | Jun 16, 2014
Company News

InSite, Senju deal

...AzaSite 1% is approved in the U.S. to treat bacterial conjunctivitis. InSite is developing AzaSite...
...2% as a once-daily, three-day treatment for ocular infections, including blepharitis, blepharoconjunctivitis or bacterial conjunctivitis. AzaSite...
BioCentury | Nov 25, 2013
Company News

Akorn, Merck sales and marketing update

...Akorn will acquire U.S. rights to ophthalmic products AzaSite 1% azithromycin, Cosopt and Cosopt PF dorzolamide/timolol...
...Akorn plans to start shipping Cosopt and Cosopt PF upon closing of the deal and AzaSite...
...AzaSite. Merck gained AzaSite through its acquisition of Inspire, which had North American rights to AzaSite...
BioCentury | Nov 18, 2013
Company News

InSite, Merck, Novartis, Pfizer ophthalmic news

...Court of Appeals for the Federal Circuit to rehear a 2011 patent infringement suit regarding AzaSite...
...AzaSite, are valid and are infringed by Sandoz's ANDA submission for a generic version of AzaSite...
...AzaSite through its acquisition of Inspire Pharmaceuticals Inc. , which had North American rights to AzaSite...
BioCentury | Oct 14, 2013
Company News

InSite Vision Inc, Merck, Novartis, Pfizer ophthalmic news

...et al., a 2011 patent infringement suit against Novartis' Sandoz International GmbH generics unit regarding AzaSite...
...cover AzaSite, are valid and infringed by Sandoz's ANDA submission for a generic version of AzaSite...
...AzaSite through its acquisition of Inspire Pharmaceuticals Inc. , which had North American rights to AzaSite...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...inhibitor fails in a Phase II trial to treat NSCLC InSite Vision Inc. (OTCBB:INSV) Twice-daily AzaSite...
BioCentury | Jul 29, 2013
Finance

Highlights of weekly biotech stock moves

...April. InSite Vision Inc. (OTCBB:INSV) plunged $0.11 (37%) to $0.19 last week after reporting that AzaSite...
...improve disease severity, is meeting with FDA in August to determine next steps (see B19). AzaSite...
Items per page:
1 - 10 of 100